Podcasts
Listen to the latest hemonc news from international experts
The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The AML Sessions: IDH inhibitors
IDH mutations are present in 20% of acute myeloid leukemia (AML) patients and the use of IDH-targeting agents has shown favorable clinical responses in AML, with ivosidenib and enasidenib (IDH1 and IDH2 inhibitors) being approved by the US F.D.A for relapsed/refractory AML patients.
In this podcast, Amir Fathi of Massachusetts General Hospital, Boston, MA, chairs a panel discussion evaluating the use of IDH inhibitors in AML and myelodysplastic syndromes, the potential of combination therapies using these agents, and the development of differentiation syndrome in AML. Dr Fathi is joined by Stephane De Botton of Gustave Roussy Institute, Villejuif, France, and Daniel Pollyea of the University of Colorado, Denver, CO.
Date: 3rd November 2020
